Guggenheim Starts Assembly Biosciences (ASMB) at Buy

Guggenheim analyst Vamil Divan initiates coverage on Assembly Biosciences (NASDAQ: ASMB) with a Buy rating and a price target of $31.00.

For an analyst ratings summary and ratings history on Assembly Biosciences click here. For more ratings news on Assembly Biosciences click here.

Shares of Assembly Biosciences closed at $11.12 yesterday.

You May Also Be Interested In

• Goldman Sachs Downgrades Ferguson Plc. (FERG) to Neutral, 'We now see better opportunities elsewhere in our coverage'
• Goldman Sachs Upgrades Rentokil Initial (RTO) to Buy
• Skyward Specialty Insurance Group (SKWD) PT Raised to $68 at Piper Sandler